摘要
目的:观察养肺解毒汤联合GP化疗方案治疗气阴两虚型非小细胞肺癌(NSCLC)患者的效果。方法:选取2020年4月至2021年4月该院收治的84例气阴两虚型NSCLC患者进行前瞻性研究,按照随机数字表法分为观察组与对照组各42例。对照组给予GP化疗方案治疗,观察组在对照组基础上联合养肺解毒汤治疗,比较两组临床疗效、中医证候积分、血清T细胞亚群指标水平和不良反应发生率。结果:观察组疾病控制率为95.24%(40/42),明显高于对照组的80.95%(34/42),差异有统计学意义(P<0.05);治疗后,两组咳嗽、气短、痰带血等中医证候积分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)水平均高于治疗前,且观察组高于对照组,两组CD8^(+)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为9.52%(4/42),明显低于对照组的26.19%(11/42),差异有统计学意义(P<0.05)。结论:养肺解毒汤联合GP化疗方案治疗气阴两虚型NSCLC患者可提高疾病控制率,改善T细胞亚群指标水平,以及降低中医证候积分和不良反应发生率,效果优于单纯GP化疗方案治疗。
Objective:To observe effects of Yangfei Jiedu decoction combined with GP chemotherapy regimen on patients with non-small cell lung cancer(NSCLC)of qi and yin deficiency type.Methods:A prospective study was conducted on 84 patients with NSCLC of qi and yin deficiency type admitted to this hospital from April 2020 to April 2021.They were divided into observation group and control group according to the random number table method,42 cases in each.The control group was given GP chemotherapy,while the observation group was treated with Yangfei Jiedu decoction on the basis of that of the control group.The clinical efficacy,the TCM syndrome score,the serum T cell subset index levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 95.24%,which was significantly higher than 80.95%in the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of TCM syndromes such as cough,shortness of breath and bloody phlegm in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+)and CD4^(+)in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the levels of CD8^(+)in the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions of the observation group was 9.52%,which was lower than 26.19%in the control group,and the difference was statistically significant(P<0.05).Conclusions:Yangfei Jiedu decoction combined with GP chemotherapy in the treatment of the NSCLC patients of qi and yin deficiency type can improve the total effective rate of treatment,improve the levels of T cell subsets,and reduce the scores of TCM syndromes and the incidence of adverse reactions.Moreover,it is superior to single GP chemotherapy.
作者
纪思宇
JI Siyu(Department of Pharmacy of the Second People’s Hospital of Liaoyang,Liaoyang 111000 Liaoning,China)
出处
《中国民康医学》
2022年第24期75-77,共3页
Medical Journal of Chinese People’s Health
关键词
气阴两虚型
非小细胞肺癌
养肺解毒汤
中医证候
T细胞亚群
不良反应
Qi and yin deficiency type
Non-small cell lung cancer
Yangfei Jiedu decoction
TCM syndrome
T cell subset
Adverse reaction
